Pharmacological Chaperoning of NAChRs: a Therapeutic Target for Parkinson's Disease

Overview

Journal Pharmacol Res

Publisher Elsevier

Specialty Pharmacology

Date 2014 Mar 6

PMID 24593907

Citations 33

Authors

Rahul Srinivasan

Brandon J Henderson

Henry A Lester

Christopher I Richards

Affiliations

Soon will be listed here.

Abstract

Chronic exposure to nicotine results in an upregulation of neuronal nicotinic acetylcholine receptors (nAChRs) at the cellular plasma membrane. nAChR upregulation occurs via nicotine-mediated pharmacological receptor chaperoning and is thought to contribute to the addictive properties of tobacco as well as relapse following smoking cessation. At the subcellular level, pharmacological chaperoning by nicotine and nicotinic ligands causes profound changes in the structure and function of the endoplasmic reticulum (ER), ER exit sites, the Golgi apparatus and secretory vesicles of cells. Chaperoning-induced changes in cell physiology exert an overall inhibitory effect on the ER stress/unfolded protein response. Cell autonomous factors such as the repertoire of nAChR subtypes expressed by neurons and the pharmacological properties of nicotinic ligands (full or partial agonist versus competitive antagonist) govern the efficiency of receptor chaperoning and upregulation. Together, these findings are beginning to pave the way for developing pharmacological chaperones to treat Parkinson's disease and nicotine addiction.

Citing Articles

Systemically circulating 17β-estradiol enhances the neuroprotective effect of the smoking cessation drug cytisine in female parkinsonian mice.

Zarate S, Garcia R, Pandey G, Srinivasan R NPJ Parkinsons Dis. 2025; 11(1):6.

PMID: 39753582 PMC: 11698717. DOI: 10.1038/s41531-024-00855-3.

Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases.

Guo F, Qin X, Mao J, Xu Y, Xie J Molecules. 2024; 29(23.

PMID: 39683859 PMC: 11643850. DOI: 10.3390/molecules29235700.

Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases.

Valles A, Barrantes F Cells. 2023; 12(16).

PMID: 37626860 PMC: 10453526. DOI: 10.3390/cells12162051.

A potential cost of evolving epibatidine resistance in poison frogs.

York J, Borghese C, George A, Cannatella D, Zakon H BMC Biol. 2023; 21(1):144.

PMID: 37370119 PMC: 10303791. DOI: 10.1186/s12915-023-01637-8.

Activation of α7-nAChRs Promotes the Clearance of α-Synuclein and Protects Against Apoptotic Cell Death Induced by Exogenous α-Synuclein Fibrils.

Zhao J, Li Y, Li Y, Xu S, Tao T, Hua Y Front Cell Dev Biol. 2021; 9:637319.

PMID: 33718373 PMC: 7947362. DOI: 10.3389/fcell.2021.637319.

References

Tumkosit P, Kuryatov A, Luo J, Lindstrom J . Beta3 subunits promote expression and nicotine-induced up-regulation of human nicotinic alpha6* nicotinic acetylcholine receptors expressed in transfected cell lines. Mol Pharmacol. 2006; 70(4):1358-68. DOI: 10.1124/mol.106.027326. View

Fagerstrom K, Pomerleau O, Giordani B, Stelson F . Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl). 1994; 116(1):117-9. DOI: 10.1007/BF02244882. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Xiao C, Srinivasan R, Drenan R, Mackey E, McIntosh J, Lester H . Characterizing functional α6β2 nicotinic acetylcholine receptors in vitro: mutant β2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells. Biochem Pharmacol. 2011; 82(8):852-61. PMC: 3162078. DOI: 10.1016/j.bcp.2011.05.005. View

Fish K . Total internal reflection fluorescence (TIRF) microscopy. Curr Protoc Cytom. 2009; Chapter 12:Unit12.18. PMC: 4540339. DOI: 10.1002/0471142956.cy1218s50. View

Miwa J, Freedman R, Lester H . Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron. 2011; 70(1):20-33. PMC: 4418790. DOI: 10.1016/j.neuron.2011.03.014. View

Marks M, Stitzel J, Collins A . Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther. 1985; 235(3):619-28. View

Vallejo Y, Buisson B, Bertrand D, Green W . Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J Neurosci. 2005; 25(23):5563-72. PMC: 2246082. DOI: 10.1523/JNEUROSCI.5240-04.2005. View

Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M . Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem. 1998; 71(6):2439-46. DOI: 10.1046/j.1471-4159.1998.71062439.x. View

10.

Mao D, Perry D, Yasuda R, Wolfe B, Kellar K . The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem. 2007; 104(2):446-56. DOI: 10.1111/j.1471-4159.2007.05011.x. View

11.

Hoozemans J, van Haastert E, Eikelenboom P, de Vos R, Rozemuller J, Scheper W . Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007; 354(3):707-11. DOI: 10.1016/j.bbrc.2007.01.043. View

12.

Dawson T, Dawson V . The role of parkin in familial and sporadic Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S32-9. PMC: 4115293. DOI: 10.1002/mds.22798. View

13.

Mudo G, Belluardo N, Fuxe K . Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm (Vienna). 2006; 114(1):135-47. DOI: 10.1007/s00702-006-0561-z. View

14.

Benwell M, Balfour D, Anderson J . Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem. 1988; 50(4):1243-7. DOI: 10.1111/j.1471-4159.1988.tb10600.x. View

15.

Champtiaux N, Gotti C, Cordero-Erausquin M, David D, Przybylski C, Lena C . Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci. 2003; 23(21):7820-9. PMC: 6740613. View

16.

Wang Y, Loo T, Bartlett M, Clarke D . Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol. 2006; 71(3):751-8. DOI: 10.1124/mol.106.029926. View

17.

Pollok B, HEIM R . Using GFP in FRET-based applications. Trends Cell Biol. 1999; 9(2):57-60. DOI: 10.1016/s0962-8924(98)01434-2. View

18.

Fenster C, Whitworth T, Sheffield E, Quick M, Lester R . Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci. 1999; 19(12):4804-14. PMC: 6782670. View

19.

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

20.

Grady S, Salminen O, McIntosh J, Marks M, Collins A . Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors. J Mol Neurosci. 2009; 40(1-2):91-5. PMC: 4386732. DOI: 10.1007/s12031-009-9263-y. View